Profile data is unavailable for this security.
About the company
Cardinal Health, Inc. is a healthcare services and products company. The Company operates through two segments: Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, over-the-counter healthcare and consumer products. This segment also operates nuclear pharmacies and cyclotron facilities; provides pharmacy management services to hospitals, as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers, and provides services to healthcare companies. The Medical segment distributes a range of medical, surgical and laboratory products, and provides services to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers. This segment also manufactures, sources and develops its own Cardinal Health brand medical and surgical products. It provides post-acute care management and transition services, and software to hospitals.
- Revenue in USD (TTM)147.66bn
- Net income in USD-4.15bn
- Incorporated1979
- Employees49.50k
- LocationCardinal Health Inc7000 Cardinal PlDUBLIN 43017-1091United StatesUSA
- Phone+1 (614) 757-3033
- Fax+1 (614) 757-6000
- Websitehttps://www.cardinalhealth.com/en.html
More ▼
Mergers & acquisitions
| Acquired company | CAH:NYQ since announced | Transaction value |
|---|---|---|
| mscripts LLC | 19.28% | -- |
| Mirixa Corp | 19.80% | -- |
Data delayed at least 15 minutes, as of Dec 06 2019 23:30 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ionis Pharmaceuticals Inc | 821.03m | 97.71m | 9.09bn | 737.00 | 94.17 | 6.80 | 108.27 | 11.07 | 0.6861 | 3.08 | 5.82 | 9.50 | 0.3193 | 24.85 | 25.73 | 1,114,022.00 | 2.72 | -3.53 | 3.21 | -4.24 | 58.00 | 27.75 | 8.52 | -10.49 | 10.31 | -- | 0.3048 | -- | 16.63 | 32.42 | -154.21 | -- | 54.38 | -- |
| Mylan NV | 11.39bn | 54.30m | 9.96bn | 35.00k | 184.47 | 0.8685 | 4.98 | 0.8743 | 0.1046 | 0.0914 | 22.08 | 22.21 | 0.353 | 2.59 | 4.43 | 325,354.30 | 0.1684 | 2.58 | 0.1986 | 3.17 | 39.38 | 43.62 | 0.4768 | 6.64 | 0.8357 | 2.76 | 0.5317 | 0.00 | -3.98 | 10.60 | -59.01 | -11.53 | 24.77 | -- |
| Elanco Animal Health Inc | 3.08bn | 93.80m | 10.10bn | 5.59k | 106.01 | 1.84 | 25.35 | 3.28 | 0.2555 | 0.2555 | 8.38 | 14.71 | 0.3419 | 1.42 | 4.52 | 551,574.30 | 1.04 | -- | 1.17 | -- | 52.24 | 49.85 | 3.04 | -2.54 | 1.67 | 4.78 | 0.3007 | -- | 6.15 | 9.72 | 125.16 | -14.65 | -- | -- |
| Neurocrine Biosciences, Inc. | 675.57m | 21.09m | 10.76bn | 585.00 | 691.47 | 18.72 | 387.99 | 15.92 | 0.1689 | 0.1689 | 7.16 | 6.24 | 0.6392 | 0.7714 | 7.98 | 1,154,819.00 | 2.00 | -16.65 | 2.74 | -17.93 | 99.04 | -- | 3.12 | -63.61 | 6.99 | 8.73 | 0.4126 | -- | 179.19 | 174.05 | 114.81 | -- | 114.61 | -- |
| EXACT Sciences Corporation | 723.70m | -215.91m | 12.70bn | 1.98k | -- | 14.96 | -- | 17.55 | -1.71 | -1.71 | 5.70 | 5.76 | 0.4428 | 4.03 | 11.66 | 366,059.20 | -13.21 | -33.75 | -16.10 | -36.94 | 74.34 | 68.50 | -29.83 | -97.50 | 2.63 | -10.08 | 0.522 | -- | 70.86 | 155.87 | 26.81 | -- | 76.69 | -- |
| Alnylam Pharmaceuticals, Inc. | 169.10m | -821.37m | 13.80bn | 1.07k | -- | 8.57 | -- | 81.60 | -7.76 | -7.76 | 1.60 | 14.44 | 0.0802 | 0.4433 | 6.57 | 158,781.20 | -38.95 | -34.42 | -43.89 | -37.49 | 91.40 | -- | -485.73 | -762.01 | 5.22 | -- | 0.00 | -- | -16.69 | 9.69 | -55.29 | -- | 99.59 | -- |
| BioMarin Pharmaceutical Inc. | 1.60bn | -42.52m | 14.36bn | 2.85k | -- | 4.67 | 226.41 | 8.96 | -0.2504 | -0.2504 | 8.89 | 17.12 | 0.3464 | 0.606 | 4.07 | 562,590.10 | -0.9191 | -5.98 | -1.07 | -6.84 | 78.88 | 81.28 | -2.65 | -19.56 | 2.53 | -14.59 | 0.2178 | -- | 13.52 | 22.14 | -3.30 | -- | 17.28 | -- |
| Cardinal Health Inc | 147.66bn | -4.15bn | 16.05bn | 49.50k | -- | 17.86 | -- | 0.1087 | -14.05 | -14.05 | 495.09 | 3.07 | 3.73 | 11.29 | 18.15 | 2,983,071.00 | -10.48 | 2.60 | -24.71 | 6.02 | 4.64 | 5.16 | -2.81 | 0.7268 | 0.4992 | 6.64 | 0.8985 | 59.41 | 6.38 | 9.83 | 300.44 | 3.22 | 5.67 | 9.50 |
| AmerisourceBergen Corp. | 179.59bn | 818.37m | 18.17bn | 22.00k | 22.95 | 6.34 | 13.92 | 0.1012 | 3.84 | 4.02 | 843.54 | 13.92 | 4.67 | 15.20 | 14.45 | 8,163,142.00 | 2.13 | 2.11 | 8.53 | 8.73 | 2.78 | 2.78 | 0.455 | 0.4435 | 0.5771 | 12.96 | 0.6002 | 43.62 | 6.94 | 8.48 | -21.75 | 23.77 | 3.24 | 11.22 |
| Seattle Genetics, Inc. | 801.42m | -304.29m | 20.14bn | 1.30k | -- | 11.30 | -- | 25.13 | -1.87 | -1.87 | 4.93 | 10.40 | 0.4373 | 0.8087 | 4.68 | 615,531.50 | -16.60 | -16.85 | -18.87 | -20.59 | 91.56 | 88.47 | -37.97 | -31.44 | 4.49 | -4.91 | 0.00 | -- | 35.76 | 19.45 | -77.40 | -- | -0.8587 | -- |
| Incyte Corporation | 2.11bn | 404.96m | 20.35bn | 1.37k | 50.68 | 8.40 | 44.20 | 9.66 | 1.86 | 1.86 | 9.71 | 11.25 | 0.7351 | 13.01 | 8.06 | 1,541,896.00 | 14.12 | -1.91 | 16.70 | -2.33 | 95.88 | 96.44 | 19.21 | -2.44 | 5.01 | -- | 0.0205 | -- | 22.50 | 39.60 | 134.97 | -- | 76.69 | -- |
Data as of Dec 06 2019. Currency figures normalised to Cardinal Health Inc's reporting currency: US Dollar USD
42.05%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2019 | 36.07m | 12.34% |
| SSgA Funds Management, Inc.as of 30 Sep 2019 | 21.78m | 7.45% |
| Macquarie Investment Management Business Trustas of 30 Sep 2019 | 15.47m | 5.29% |
| BlackRock Fund Advisorsas of 30 Sep 2019 | 15.27m | 5.22% |
| Mellon Investments Corp.as of 30 Sep 2019 | 6.93m | 2.37% |
| SunAmerica Asset Management LLCas of 30 Sep 2019 | 6.73m | 2.30% |
| Invesco Capital Management LLCas of 30 Sep 2019 | 5.73m | 1.96% |
| Columbia Management Investment Advisers LLCas of 30 Sep 2019 | 5.29m | 1.81% |
| Fidelity Management & Research Co.as of 30 Sep 2019 | 4.86m | 1.66% |
| Geode Capital Management LLCas of 30 Sep 2019 | 4.83m | 1.65% |
More ▼
Data from 30 Sep 2019 - 30 Sep 2019Source: FactSet Research Systems Inc.
